TD Cowen Trims Theravance Biopharma (NASDAQ:TBPH) Target Price to $9.00

Theravance Biopharma (NASDAQ:TBPH) had its price objective cut by TD Cowen from $10.00 to $9.00 in a report issued on Tuesday, Benzinga reports. They currently have a hold rating on the biopharmaceutical company’s stock.

TBPH has been the topic of several other reports. StockNews.com downgraded shares of Theravance Biopharma from a buy rating to a hold rating in a research report on Thursday, August 1st. BTIG Research assumed coverage on shares of Theravance Biopharma in a research report on Friday, April 12th. They set a buy rating and a $21.00 target price on the stock. SVB Leerink cut shares of Theravance Biopharma from an outperform rating to a market perform rating and reduced their price target for the stock from $15.00 to $10.00 in a report on Tuesday. Finally, HC Wainwright reiterated a buy rating and set a $20.00 price objective on shares of Theravance Biopharma in a report on Wednesday, May 29th. Four investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat, the company presently has an average rating of Hold and a consensus target price of $13.75.

Theravance Biopharma Stock Performance

Shares of NASDAQ TBPH traded down $0.02 during trading hours on Tuesday, hitting $7.66. 316,595 shares of the stock were exchanged, compared to its average volume of 410,832. Theravance Biopharma has a 1-year low of $7.44 and a 1-year high of $11.71. The company has a market cap of $372.51 million, a PE ratio of -8.91 and a beta of 0.24. The company’s fifty day simple moving average is $9.01 and its two-hundred day simple moving average is $9.05.

Theravance Biopharma (NASDAQ:TBPH) last released its quarterly earnings data on Monday, August 5th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.25). The business had revenue of $14.26 million during the quarter, compared to analyst estimates of $15.81 million. Theravance Biopharma had a negative net margin of 73.61% and a negative return on equity of 20.63%. During the same period last year, the business earned ($0.28) earnings per share. As a group, sell-side analysts expect that Theravance Biopharma will post -0.42 EPS for the current fiscal year.

Insider Activity at Theravance Biopharma

In other news, major shareholder Eli Samaha acquired 999,800 shares of Theravance Biopharma stock in a transaction on Wednesday, August 7th. The stock was acquired at an average cost of $7.80 per share, with a total value of $7,798,440.00. Following the transaction, the insider now owns 9,511,150 shares of the company’s stock, valued at approximately $74,186,970. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, SVP Rhonda Farnum sold 4,000 shares of the business’s stock in a transaction dated Wednesday, July 10th. The shares were sold at an average price of $9.00, for a total value of $36,000.00. Following the transaction, the senior vice president now directly owns 335,965 shares of the company’s stock, valued at approximately $3,023,685. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Eli Samaha purchased 999,800 shares of Theravance Biopharma stock in a transaction that occurred on Wednesday, August 7th. The shares were bought at an average price of $7.80 per share, with a total value of $7,798,440.00. Following the transaction, the insider now owns 9,511,150 shares of the company’s stock, valued at approximately $74,186,970. The disclosure for this purchase can be found here. 6.90% of the stock is owned by insiders.

Institutional Trading of Theravance Biopharma

Several hedge funds have recently made changes to their positions in the company. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Theravance Biopharma by 31.4% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,330 shares of the biopharmaceutical company’s stock worth $105,000 after acquiring an additional 2,227 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its position in shares of Theravance Biopharma by 66.4% in the first quarter. China Universal Asset Management Co. Ltd. now owns 9,583 shares of the biopharmaceutical company’s stock valued at $86,000 after acquiring an additional 3,824 shares during the period. Gerber LLC purchased a new position in Theravance Biopharma during the fourth quarter valued at approximately $112,000. Simplicity Solutions LLC purchased a new position in Theravance Biopharma during the fourth quarter valued at approximately $141,000. Finally, Bleakley Financial Group LLC bought a new stake in Theravance Biopharma during the 4th quarter worth approximately $141,000. 99.10% of the stock is currently owned by institutional investors.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.